Specifically, we hypothesized that naloxone, a preferential μ−opioid receptor antagonist, would block the effect of oxytocin in tests of anxiety- and depression-like behavior in mice, and that the effect of naloxone would be mediated by μ−, but not κ−opioid receptors. The gene discussed is OXT; the disease is depressive symptom measurement.